Recent evidence reveals similarities in various areas, including brain connectivity and dopamine synthesis patterns between schizophrenia and bipolar disorder. This biological homogeneity is found not only in two diseases but also in various psychiatric disorders. The current phenotypes-based diagnostic classification system involves a heterogeneity of mental illness. Recently, the movement to reclassify existing diseases centered on biomarkers has drawn attention. The 2008 NIMH Strategic Plan calls for NIMH to “Develop, for research purposes, new ways of classifying mental disorders based on dimensions of observable behavior and neurobiological measures.” However, there is still a lack of research that attempts a cross-diagnostic approach to make this possible.
This topic aims to examine the differences between neuroimaging biomarker-based classification and current phenotypes-based mental disorders. Differentiating the clinical group and non-clinical group that does not show symptoms despite having specific pathologies is crucial in identifying the neuroimaging biomarkers that distinguish the manifestation and compensation of the psychotic symptoms. Reclassifying with trans-diagnostical samples, including psychotic disorders, will explain the pathophysiology of the onset of schizophrenia and the manifestation of psychosis symptoms. This will also suggest another possibility of novel treatments or prevention.
• To examine one or more other mental illnesses, including schizophrenia, bipolar disorders, and healthy individuals as a single sample.
• Reclassification of transdiagnostic samples in quantitative ways, e.g., approach in RDoC, includes MRI, DTI, fMRI, PET etc.
• It covers everything from simple classical statistical analysis to methods of data science.
• More preferred are studies that examine the treatment response by attempting neuromodulation with specific brain regions or pathways.
All formats, including original research, reviews, opinions, perspective are preferred.
Recent evidence reveals similarities in various areas, including brain connectivity and dopamine synthesis patterns between schizophrenia and bipolar disorder. This biological homogeneity is found not only in two diseases but also in various psychiatric disorders. The current phenotypes-based diagnostic classification system involves a heterogeneity of mental illness. Recently, the movement to reclassify existing diseases centered on biomarkers has drawn attention. The 2008 NIMH Strategic Plan calls for NIMH to “Develop, for research purposes, new ways of classifying mental disorders based on dimensions of observable behavior and neurobiological measures.” However, there is still a lack of research that attempts a cross-diagnostic approach to make this possible.
This topic aims to examine the differences between neuroimaging biomarker-based classification and current phenotypes-based mental disorders. Differentiating the clinical group and non-clinical group that does not show symptoms despite having specific pathologies is crucial in identifying the neuroimaging biomarkers that distinguish the manifestation and compensation of the psychotic symptoms. Reclassifying with trans-diagnostical samples, including psychotic disorders, will explain the pathophysiology of the onset of schizophrenia and the manifestation of psychosis symptoms. This will also suggest another possibility of novel treatments or prevention.
• To examine one or more other mental illnesses, including schizophrenia, bipolar disorders, and healthy individuals as a single sample.
• Reclassification of transdiagnostic samples in quantitative ways, e.g., approach in RDoC, includes MRI, DTI, fMRI, PET etc.
• It covers everything from simple classical statistical analysis to methods of data science.
• More preferred are studies that examine the treatment response by attempting neuromodulation with specific brain regions or pathways.
All formats, including original research, reviews, opinions, perspective are preferred.
